| INTRODUCTION
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine carcinoma of the skin. It affects mostly elderly Caucasian patients, and males slightly more frequent than females. The predominant locations are the head and neck region, followed by the extremities. 1 These sunexposed locations support the assumption that UV exposure increases the risk of MCC. 2 Other factors associated with an increased risk are immunosuppression and Merkel Cell Polyomavirus (MCV). 3 In rare cases no primary tumor can be found, similarly to melanoma which it is often compared to. Possibly, the immune system is responsible in initiating regression of the primary tumor. 4 MCC is characterized by an aggressive metastatic spread. At diagnosis, approximately 26% of the patients have nodal involvement.
Loco-regional recurrence is seen in 26-60%, often within 2 years after diagnosis. 5, 6 Overall survival ranges from 30 to 60%. 7, 8 The rapid spread and poor survival of MCC justifies an aggressive approach in its treatment, which consists mainly of surgical treatment followed by adjuvant radiation therapy (XRT) for early stage MCC. 9, 10 Chemotherapy is indicated only for patients with distant metastases, with a quick but often short response. 11, 12 Adjuvant chemotherapy is not of benefit. 13 Immunotherapy has promising results but has not established a definitive role in the treatment of MCC yet. 14 In the last decade, the reported incidence has increased rapidly. [15] [16] [17] [18] [19] This may be partly explained by better recognition and uniform staining but also increased registration as an unique entity.
Literature on MCC is quite limited. Most studies are retrospective and single center. 13, 20, 21 Several large database series using the Surveillance, Epidemiology, and End Results program (SEER) and the National Cancer Data Base (NCDB) investigated MCC. Unfortunately, these series often lacked data on treatment, recurrence, and cause of death. 5, 7, 91, 9, 22, 23 The aims of the current study are to describe treatment, relapse, overall survival (OS),and more specifically, MCC related death of patients with MCC in two large melanoma and neuroendocrine tumor expert-centers in the Netherlands.
| PATIENTS AND METHODS
This study was performed in accordance with institutional ethical guidelines in both clinics. All patients with histologically confirmed MCC between January 1990 and December 2014 were included. Patients were identified using the clinics' tumor registry administration. A retrospective review of each patients' medical record was completed. 
| RESULTS
We identified 360 patients of which nine patients were excluded from analysis according exclusion criteria. The cohort consisted of 153 male (44%) and 198 female (56%) patients with a median age of 74 years (range 28-94). Baseline characteristics are summarized in Table 1 . A total of 52 patients (15%) were immune compromised of which 7% due to auto-immune disorders, 6% due to hemato-oncological malignancies, 2% due to an previous organ transplantation an one patient because of an HIV infection. A total of 104 patients (30%) had previous malignancies. Medical history and comorbidities are more specifically outlined in Table 1 . patients (18%) death occurred due to other causes. In seven patients (2%) no cause of death was registered. Of these patients four patients had nodal involvement and two patients had distant metastases. The remaining patient had localized disease only. Two patients wished to be withdrawn from FU and one patient transferred to another clinic due to urgent cardiac co-morbidity. Of the patients still alive at last FU, 168 patients (48%) had no evidence of disease and 54 patients (15%) were alive with disease (Table 2) .
Relapse during FU occurred in 134 patients (38%) of which 86% provides all other univariable analyses) In multivariable analyses adjuvant XRT was associated with a significant lower relapse (SDH 0.54; CI 0.3-09).
This association was not seen for either OS or MCC related death. Lymph node metastases at diagnoses were associated with relapse (SDH 1.9; CI 1.1-3.3) and MCC related death (SDH 2.7; CI 1.1-6.6).
Gender, age >74 years, PTS >2 cm and loco-regional metastasis at time of diagnosis were associated with a decreased OS (Table 3 ). Only patients with a known PTS (n = 210, 60%) could be included in our multivariable analysis. Primary tumor location was not associated with any type of survival. For MCC related death, the male gender (SDH 3.1; CI 1.2-7.9) was the strongest independent prognostic predictor ( Table 3) .
| DISCUSSION
Our study confirms the poor OS and high relapse rate reported in other studies, however we found a low MCC related death rate. This indicates that a significant number of elderly MCC patients die due to other causes than MCC. In the aged MCC population with high comorbidity, the low MCC related death is important to consider when deciding on a therapy strategy. There is significant evidence that the immune system plays a role in developing MCC and possibly affects survival. MCC is associated with MCV and the use of immunosuppressive medication; the immune system is possibly responsible for the spontaneous regression of the primary tumor. 3, 4 Additionally, T-cell density at the periphery of the tumor is associated with an improved OS. 36 Gender related disparities concerning the immune system are already known, for instance in the prevalence of autoimmune disease. 37 Hence, we believe the difference in survival between genders could be immune related. More research PT, primary tumor; XRT, radiation therapy. *Performed for group with known PT size (n = 210, 60%). All significant (P < 0,05) results are given in bold.
should aim at explaining the exact mechanism responsible for the worse survival of the male patients.
To our knowledge, our cohort is the second largest institutional study in literature. 13, 20, 28, [38] [39] [40] [41] Several population-based series have been published. 5, 7, 9, 19, 22, 23 While the number of patients from such studies is enlarged association, yet due to the missing PTS our dataset is likely to lack power. Furthermore, nodal metastases at diagnosis was a prognostic factor. As we see more missing PTS early in our study we believe this is because of the poor (non-electronic) documentation in earlier decades.
Synchronously to PTS, data on tumor depth or lymph vascular invasion was missing. Smith et al 45 have shown their prognostic relevance.
Though, they encountered comparable impaired data and analysis was ultimately performed on 160 of 375 patients.
Besides extent of the disease at diagnosis, the method used to determine staging is associated with survival. Heterogeneous treatment regimens were given but often consisted of surgery followed by LND and/or adjuvant XRT. Adjuvant XRT was associated with reduced recurrence of MCC. The male gender and locoregional metastasis at time of diagnosis were negative independent predictors of MCC related death. Due to the rarity and heterogeneous treatment of MCC patients, centralized care for MCC is desirable.
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